CytomX Therapeutics, Inc.

Listed Company

CTMXCIK 0001501989NasdaqAcceleratedPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

$76.20M

Net Income

$-17.37M

Total Assets

$151.57M

Equity

$99.01M

Shares Out

170.19M

Op. Cash Flow

$-75.59M

Business

CytomX Therapeutics, Inc. develops masked, conditionally activated biologic therapeutics for oncology using its proprietary PROBODY® platform to localize activity to the tumor microenvironment. The company’s products and services include multi-modality biologics such as antibody-drug conjugates (ADCs), T-cell engagers (TCEs), cytokines, and mRNA-encoded masked biologics, with clinical-stage candidates including CX-2051, CX-801 and CX-904. CytomX operates through internal discovery and development programs and strategic collaborations and license alliances with global biopharmaceutical partners. It conducts clinical trials and advances programs primarily in the United States and through international development and commercialization partnerships.

Summary from filing dated 2025-03-06

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenue	76	138	101	53	37
Research and development	69	83	78	112	114
General and administrative	30	30	30	43	39
Total operating expenses	99	113	108	154	153
Income (loss) from operations	−22	25	−6	−101	−116
Interest income	5	7	10	2	255,000
Other income (expense), net	28,000	−38,000	−30,000	340,000	−83,000
Income (loss) before income taxes	−17	32	3	−99	−116
Provision for income taxes	238,000	224,000	4	0	0
Net income (loss)	−17	32	—	—	—
Net income (loss)	−17	32	−569,000	−99	−116
Deemed dividend on warrants	−3	0	—	—	—
Net income (loss) attributable to common stockholders	−20	32	—	—	—
Unrealized gain (loss) on available-for-sale investments, net of tax	84,000	−68,000	85,000	252,000	−195,000
Total comprehensive income (loss)	−17	32	−484,000	−99	−116
Net income (loss) per share, Basic	−0.15	0.38	−0.01	−1.51	−1.81
Net income (loss) per share, Diluted	−0.15	0.38	−0.01	−1.51	−1.81
Shares used to compute net income (loss) per share, Basic	138	84	74	66	64
Shares used to compute net income (loss) per share, Diluted	138	85	74	66	64

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2022 2022-09-30
Cash and cash equivalents	13	38	17	194	—
Short-term investments	124	63	157	0	—
Accounts receivable	2	3	3	36	—
Prepaid expenses and other current assets	5	4	5	7	—
Total current assets	144	107	183	237	—
Property and equipment, net	1	2	4	5	—
Intangible assets, net	438,000	583,000	729,000	875,000	—
Goodwill	949,000	949,000	949,000	949,000	—
Restricted cash	2	1	917,000	917,000	—
Operating lease right-of-use asset	3	8	12	16	—
Other assets	31,000	66,000	83,000	27,000	—
Total assets	152	121	202	261	—
Accounts payable	1	1	1	3	—
Accrued liabilities	14	12	18	24	—
Operating lease liabilities - short term	4	5	5	4	—
Deferred revenue, current portion	27	67	132	121	87
Total current liabilities	47	86	156	153	124
Deferred revenue, net of current portion	2	27	80	180	168
Operating lease liabilities - long term	0	4	9	14	—
Other long-term liabilities	4	4	4	0	—
Total liabilities	53	121	249	347	307
Commitments and contingencies (Note 10)	—	—	—	—	—
Convertible preferred stock, $0.00001 par value; 10,000,000 shares authorized and no shares issued and outstanding	0	0	—	—	—
Common stock, $0.00001 par value; 300,000,000 and 150,000,000 shares authorized, and 170,186,365 and 80,099,889 shares issued and outstanding at December 31, 2025 and 2024, respectively	2,000	1,000	1,000	1,000	—
Additional paid-in capital	811	691	676	637	—
Accumulated other comprehensive income	111,000	27,000	95,000	10,000	—
Accumulated deficit	−712	−692	−723	−723	−714
Total stockholders' equity (deficit)	99	−456,000	−47	−86	−81
Total liabilities and stockholders' equity (deficit)	152	121	202	261	226

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Amortization of intangible assets	146,000	146,000	146,000	146,000	146,000
Depreciation and amortization	1	2	2	2	3
Impairment loss on machinery and equipment	402,000	106,000	0	254,000	—
Accretion of discounts on short-term investments	−2	−5	−7	−52,000	272,000
Stock-based compensation expense	6	8	9	13	13
Non-cash lease expense	4	4	4	3	3
Accounts receivable	1	329,000	33	−35	8,000
Prepaid expenses and other assets	−1	1	2	−3	3
Accounts payable	221,000	−297,000	−1	68,000	−139,000
Accrued liabilities and other long-term liabilities	−3	−10	−7	−10	—
Deferred revenue	−66	−118	−89	17	−34
Net cash used in operating activities	−76	−86	−56	−111	−119
Purchases of property and equipment	−220,000	−310,000	−840,000	−2	−2
Purchases of short term investments	−193	−155	−425	0	−100
Maturities of short term investments	133	256	275	100	124
Net cash provided by (used in) investing activities	−60	100	−151	98	22
Proceeds from issuance of pre-funded warrants and warrants, net of issuance cost	0	0	30	0	—
Proceeds from issuance of common stock, net of issuance cost	110	7	—	0	108
Proceeds from employee stock purchase plan and exercise of stock options	811,000	613,000	561,000	648,000	3
Net cash provided by financing activities	110	8	30	648,000	110
Net increase (decrease) in cash, cash equivalents and restricted cash	−25	21	−176	−12	14
Purchases of property and equipment in accounts payable and accrued liabilities	0	8,000	75,000	6,000	83,000
Deemed dividend on warrants	3	0	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro